HRP20230851T1 - Sprječavanje i liječenje migrene - Google Patents
Sprječavanje i liječenje migrene Download PDFInfo
- Publication number
- HRP20230851T1 HRP20230851T1 HRP20230851TT HRP20230851T HRP20230851T1 HR P20230851 T1 HRP20230851 T1 HR P20230851T1 HR P20230851T T HRP20230851T T HR P20230851TT HR P20230851 T HRP20230851 T HR P20230851T HR P20230851 T1 HRP20230851 T1 HR P20230851T1
- Authority
- HR
- Croatia
- Prior art keywords
- migraine
- symptoms
- accordance
- compound
- image
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title claims 21
- 206010027599 migraine Diseases 0.000 title claims 21
- 230000002265 prevention Effects 0.000 title claims 12
- 150000001875 compounds Chemical class 0.000 claims 20
- 208000024891 symptom Diseases 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- 159000000000 sodium salts Chemical class 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N glycerine triacetate Natural products CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (1R)-1,3-butanediol Natural products CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical class C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical class NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 206010027951 Mood swings Diseases 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 206010072731 White matter lesion Diseases 0.000 claims 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical class NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma, naznačen time što se navedeni spoj bira iz skupine koju čine
a. β-hidroksimaslačna kiselina (βHB), ili njezina farmaceutski prihvatljiva sol,
b. acetoacetat (AcAc), ili njegova farmaceutski prihvatljiva sol,
c. metabolički preteča βHB ili AcAc, kojeg se bira između
– 1,3-butandiola (CAS br. 107 88 0) i
– triacetina (CAS br. 102-76-1),
ili njegove farmaceutski prihvatljive soli, i
d. spoj koji sadrži acetoacetil- ili 3-hidroksibutiratni dio kojeg opisuje bilo koji od
– (3R)-hidroksibutil-(3R)-hidroksibutirata,
– acetoacetil-1,3-butandiola,
– acetoacetil-R-3-hidroksibutirata i
– acetoacetilglicerola,
ili kojeg prikazuje bilo koja od formula:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s patentnim zahtjevom 1, naznačen time što se navedeni spoj bira između βHB, metaboličkog preteče βHB, spoja koji sadrži 3-hidroksibutiratni dio, te njegove farmaceutski prihvatljive soli.
3. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni spoj D-βHB, ili njegova farmaceutski prihvatljiva sol.
4. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od prethodnih patentnih zahtjeva ili d-β-hidroksibutirat-d-1,3-butandiol,
[image]
ili
[image]
,
ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma, naznačen time što se navedenu farmaceutski prihvatljivu sol bira između kalijeve soli, natrijeve soli, kalcijeve soli, magnezijeve soli, argininske soli, lizinske soli, histidinske soli, ornitinske soli, kreatinske soli, agmatinske soli, citrulinske soli, metilglukaminske soli i karnitinske soli, ili kombinacije navedenih soli, osobito kombinacije kalcijeve i natrijeve soli, po mogućnosti gdje navedena kombinacija soli sadrži kombinaciju lizinske soli i kalcijeve, kalijeve, magnezijeve i/ili natrijeve soli, osobito kombinaciju lizinske, kalcijeve i natrijeve soli.
5. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeno liječenje ili sprječavanje uključuje smanjivanje učestalosti napadaja migrene; smanjivanje težine napadaja migrene; smanjivanje težine simptoma migrene; sprječavanje napredovanje bolesti; sprječavanje kronifikacije bolesti.
6. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni simptomi migrene uključuju najmanje dva od sljedećih simptoma: umjerenu do jaku, pretežno jednostranu glavobolju, osjetljivost na svjetlo, buku i/ili miris, mučnina ili gađenje, bolno lice, bolne oči, poremećenu ravnotežu, poteškoće u pronalaženju riječi, druge neurološke simptome, poput senzoričkih ili motoričkih poremećaja, alodiniju ili bilo koju drugu od značajki za koje se zna da prate, prethode ili slijede nakon napadaja migrene, poput zamora, mučnine, kognitivnih poremećaja, umora, velike gladi ili žeđi, smanjenog libida, deprezije, manije, promjenjivog raspoloženja, kao i promjene u strukturi i funkciji mozga, poput lezija bijele tvari ili poremećaja u funkcionalnoj povezivosti.
7. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni spoj treba primijeniti prije pojave jednog ili više simptoma napadaja migrene navedenih u patentnom zahtjevu 6.
8. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je dnevna doza koju treba primijeniti 0,05 g/kg do 1 g/kg tjelesne težine, osobito 0,1 g/kg do 0,7 g/kg tjelesne težine, specifičnije 0,2 g/kg do 0,4 g/kg tjelesne težine.
9. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s patentnim zahtjevom 8, naznačen time što je navedena dnevna doza podijeljena na jednu do šest doza, osobito na dvije ili tri doze.
10. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s patentnim zahtjevom 8 ili 9, naznačen time što navedena dnevna doza treba primijeniti u vremenskom periodu od najmanje mjesec dana, osobito najmanje 6 mjeseci, specifičnije najmanje godinu dana, još specifičnije 2 godine.
11. Farmaceutski pripravak namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, po mogućnosti što navedeni farmaceutski pripravak je kombinacijski medikament koji dodatno sadrži aminokiselinu koju se bira iz skupine koju čine leucin, lizin, izoleucin, triptofan, tirozin i fenilalanin.
12. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je sadržaj spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 11 najmanje 25% (tež./tež.), osobito najmanje 35% (tež./tež.), specifičnije 50% do 100% (tež./tež.).
13. Farmaceutski pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je formuliran za oralnu primjenu, po mogućnosti u obliku praška za oralnu primjenu.
14. Farmaceutski pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je navedeni farmaceutski pripravak napitak.
15. Spoj namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od patentnih zahtjeva 1 do 10 ili farmaceutski pripravak namijenjen upotrebi u postupku liječenja ili sprječavanja migrene i/ili njezinih simptoma u skladu s bilo kojim od patentnih zahtjeva 11 do 14, naznačeni time što primjena navedenog spoja ili farmaceutski pripravak na subjektu uzrokuje povišenje razine ketonskih tijela (KB) u krvi do 0,3 mM do 6 mM, osobito do 0,4 mM do 4 mM, još specifičnije do 1 mM do 4 mM.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16206018 | 2016-12-21 | ||
EP17154258 | 2017-02-01 | ||
EP17832224.4A EP3558280B1 (en) | 2016-12-21 | 2017-12-20 | Migraine prevention and treatment |
PCT/EP2017/083880 WO2018115158A1 (en) | 2016-12-21 | 2017-12-20 | Migraine prevention and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230851T1 true HRP20230851T1 (hr) | 2023-11-10 |
Family
ID=61005774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230851TT HRP20230851T1 (hr) | 2016-12-21 | 2017-12-20 | Sprječavanje i liječenje migrene |
Country Status (17)
Country | Link |
---|---|
US (2) | US11166928B2 (hr) |
EP (2) | EP4245368A3 (hr) |
JP (2) | JP2020504746A (hr) |
KR (1) | KR102610870B1 (hr) |
CN (1) | CN110087642B (hr) |
AU (2) | AU2017384625B2 (hr) |
CA (1) | CA3046415A1 (hr) |
DK (1) | DK3558280T3 (hr) |
ES (1) | ES2948609T3 (hr) |
FI (1) | FI3558280T3 (hr) |
HR (1) | HRP20230851T1 (hr) |
HU (1) | HUE062536T2 (hr) |
LT (1) | LT3558280T (hr) |
PL (1) | PL3558280T3 (hr) |
RU (1) | RU2753057C9 (hr) |
SI (1) | SI3558280T1 (hr) |
WO (1) | WO2018115158A1 (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
FI3558280T3 (fi) * | 2016-12-21 | 2023-07-13 | Univ Kinderspital Beider Basel | Migreenin ennaltaehkäisy ja hoito |
US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
BR112021015861A2 (pt) * | 2019-03-22 | 2021-10-05 | Société des Produits Nestlé S.A. | Métodos que usam administração de triglicerídeos de cadeia média (tcm) antes de uma refeição para aumentar a produção de cetonas a partir dos tcms |
US20220257546A1 (en) | 2019-05-10 | 2022-08-18 | Ketoswiss Ag | Ketone bodies enclosed in microbeads |
BR112021025045A2 (pt) * | 2019-06-12 | 2022-02-01 | Ioi Oleo Gmbh | Processo para a produção de ésteres à base de poliol de ácidos 3-hidroxicarboxílicos capeados com acila |
BR112021025043A2 (pt) * | 2019-06-12 | 2022-02-01 | Ioi Oleo Gmbh | Processo para a produção de ácidos 3-hidroxicarboxílicos capeados com acila assim como seus sais e ésteres |
WO2023001724A1 (en) | 2021-07-17 | 2023-01-26 | Ketoswiss Ag | Combination of a ketone body or ketogenic compound with an analgesic or antioxidant |
WO2023166069A1 (en) | 2022-03-02 | 2023-09-07 | N.V. Nutricia | Fatty acids for ketosis control |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61501569A (ja) * | 1984-03-01 | 1986-07-31 | ア−ク,バ−ノン | 脊椎動物及びその他の生物において血糖水準を低下させる方法 |
JPH0665458A (ja) | 1992-08-21 | 1994-03-08 | Nippon Oil & Fats Co Ltd | 塩素含有樹脂組成物 |
US5420335A (en) | 1993-09-30 | 1995-05-30 | Birkhahn; Ronald H. | Parenteral nutrients based on watersoluble glycerol bisacetoacetates |
KR100839689B1 (ko) * | 1997-03-17 | 2008-06-18 | 비티지 인터내셔널 리미티드 | 치료용 조성물 |
WO2000015216A1 (en) * | 1998-09-15 | 2000-03-23 | Btg International Limited | Therapeutic compositions (ii) |
US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
WO2008005818A1 (en) * | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
KR20110115589A (ko) | 2009-01-24 | 2011-10-21 | 파이토팜 피엘씨 | 신경영양인자가 매개된 장애의 치료 |
GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
CN103877118A (zh) | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | 一种由醋丙甲泼尼龙、氧化锌组成的药物组合物 |
US20160078782A1 (en) * | 2014-09-17 | 2016-03-17 | The Trustees Of Boston College | Glucose Ketone Index for MetabolicTherapy |
US20180200220A1 (en) * | 2015-07-10 | 2018-07-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources |
FI3558280T3 (fi) * | 2016-12-21 | 2023-07-13 | Univ Kinderspital Beider Basel | Migreenin ennaltaehkäisy ja hoito |
US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
US10500182B2 (en) | 2018-01-10 | 2019-12-10 | Robert Firger | Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache |
-
2017
- 2017-12-20 FI FIEP17832224.4T patent/FI3558280T3/fi active
- 2017-12-20 AU AU2017384625A patent/AU2017384625B2/en active Active
- 2017-12-20 JP JP2019534680A patent/JP2020504746A/ja active Pending
- 2017-12-20 KR KR1020197021346A patent/KR102610870B1/ko active IP Right Grant
- 2017-12-20 CA CA3046415A patent/CA3046415A1/en active Pending
- 2017-12-20 SI SI201731394T patent/SI3558280T1/sl unknown
- 2017-12-20 EP EP23176972.0A patent/EP4245368A3/en active Pending
- 2017-12-20 PL PL17832224.4T patent/PL3558280T3/pl unknown
- 2017-12-20 US US16/472,309 patent/US11166928B2/en active Active
- 2017-12-20 CN CN201780079158.4A patent/CN110087642B/zh active Active
- 2017-12-20 LT LTEPPCT/EP2017/083880T patent/LT3558280T/lt unknown
- 2017-12-20 ES ES17832224T patent/ES2948609T3/es active Active
- 2017-12-20 RU RU2019122562A patent/RU2753057C9/ru active
- 2017-12-20 WO PCT/EP2017/083880 patent/WO2018115158A1/en unknown
- 2017-12-20 HU HUE17832224A patent/HUE062536T2/hu unknown
- 2017-12-20 HR HRP20230851TT patent/HRP20230851T1/hr unknown
- 2017-12-20 DK DK17832224.4T patent/DK3558280T3/da active
- 2017-12-20 EP EP17832224.4A patent/EP3558280B1/en active Active
-
2021
- 2021-06-01 US US17/335,319 patent/US11890264B2/en active Active
-
2022
- 2022-03-07 AU AU2022201565A patent/AU2022201565B2/en active Active
- 2022-08-18 JP JP2022130419A patent/JP2022166218A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022166218A (ja) | 2022-11-01 |
RU2019122562A3 (hr) | 2021-01-27 |
AU2017384625A1 (en) | 2019-06-13 |
SI3558280T1 (sl) | 2023-10-30 |
US20190374490A1 (en) | 2019-12-12 |
AU2022201565A1 (en) | 2022-03-31 |
WO2018115158A1 (en) | 2018-06-28 |
KR20190099486A (ko) | 2019-08-27 |
RU2753057C9 (ru) | 2021-09-10 |
AU2022201565B2 (en) | 2023-07-06 |
ES2948609T3 (es) | 2023-09-14 |
AU2017384625B2 (en) | 2021-12-16 |
US20210338618A1 (en) | 2021-11-04 |
EP3558280A1 (en) | 2019-10-30 |
PL3558280T3 (pl) | 2023-10-16 |
US11890264B2 (en) | 2024-02-06 |
RU2753057C2 (ru) | 2021-08-11 |
HUE062536T2 (hu) | 2023-11-28 |
US11166928B2 (en) | 2021-11-09 |
CN110087642A (zh) | 2019-08-02 |
KR102610870B1 (ko) | 2023-12-06 |
EP3558280B1 (en) | 2023-06-07 |
EP4245368A2 (en) | 2023-09-20 |
JP2020504746A (ja) | 2020-02-13 |
FI3558280T3 (fi) | 2023-07-13 |
EP4245368A3 (en) | 2024-01-03 |
DK3558280T3 (da) | 2023-08-21 |
RU2019122562A (ru) | 2021-01-27 |
CN110087642B (zh) | 2022-12-27 |
LT3558280T (lt) | 2023-10-10 |
CA3046415A1 (en) | 2018-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230851T1 (hr) | Sprječavanje i liječenje migrene | |
JP2020504746A5 (hr) | ||
AU765038B2 (en) | Method for the treatment of insomnia | |
JP2018520189A5 (hr) | ||
BRPI0517662A (pt) | partìculas de ramipril estabilizadas revestidas, processo para o revestimento de ramipril, composição farmacêutica oral sólida, métodos para evitar e tratar distúrbios cardiovasculares, e, processo para fabricar uma composição farmacêutica | |
JP2023145496A (ja) | 神経細胞損傷の治療のためのアミノ酸組成物 | |
JP2008536940A (ja) | 頭痛の治療のためのトポイラメート組成物 | |
JP2015526481A (ja) | 片頭痛の治療用組成物 | |
JP2016153434A (ja) | 片頭痛および他の適応症の処置のための方法およびシステム | |
RU2019111096A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
JP6441825B2 (ja) | フィラーの効能維持用組成物 | |
RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
JP2016050198A (ja) | 睡眠障害改善剤 | |
JP4812968B2 (ja) | 注意欠陥多動性障害改善用組成物 | |
US10052281B2 (en) | Local administration-type pharmaceutical for improving dysphagia | |
BE1023090B1 (fr) | Composition | |
RU2005125633A (ru) | Способ получения инъекционной лекарственной формы фосфолипидного препарата "фосфоглив" для лечения и профилактики острых и хронических заболеваний печени | |
AU2014209028C1 (en) | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor | |
JP6055180B2 (ja) | 組成物 | |
CA3071385A1 (en) | Substituted cycloalkanes for managing nephrogenic diabetes insipidus | |
US9974768B2 (en) | Pharmaceutical for improving dysphagia | |
JP2022520962A (ja) | 筋痙攣の予防及び治療のためのケイ素及びマグネシウムの組合せ物 | |
CA2959004A1 (en) | Composition for improving cognitive function | |
CA3010857A1 (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate |